Aripiprazole

Hospital Pharmacy

Volumn 38, Issue 3, 2003, Pages 247-254

  Cada, Dennis J ^b   Levien, Terri ^a   Baker, Danial E ^a  

^a WASHINGTON STATE UNIVERSITY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; CARBAMAZEPINE; CLOZAPINE; DEXTROMETHORPHAN; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR STIMULATING AGENT; DOPAMINE 3 RECEPTOR; ERYTHROMYCIN; FAMOTIDINE; FLUOXETINE; HALOPERIDOL; KETOCONAZOLE; LITHIUM; OLANZAPINE; OMEPRAZOLE; PAROXETINE; PROLACTIN; QUETIAPINE; QUINIDINE; RISPERIDONE; SEROTONIN 1A AGONIST; SEROTONIN 2A ANTAGONIST; VALPROIC ACID; WARFARIN;

AGITATION; AKATHISIA; AMBLYOPIA; ANXIETY DISORDER; ARTHROPATHY; ASTHENIA; CLINICAL TRIAL; COGNITION; CONSTIPATION; COUGHING; DRUG ACTIVITY; DRUG ANTAGONISM; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; EXTRAPYRAMIDAL SYMPTOM; FEVER; HEADACHE; HUMAN; HYPERSALIVATION; INSOMNIA; MYALGIA; NAUSEA; NERVOUSNESS; NONHUMAN; ORTHOSTATIC HYPOTENSION; PHARYNGITIS; PSYCHOSIS; RASH; RECEPTOR AFFINITY; REVIEW; RHINITIS; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SIDE EFFECT; SOMNOLENCE; SYNCOPE; TACHYCARDIA; TOOTH DISEASE; TREATMENT OUTCOME; TREMOR; VERTIGO; VIRUS INFECTION; VISUAL IMPAIRMENT; VOMITING; WEIGHT GAIN; XEROSTOMIA;

EID: 0037339947     PISSN: 00185787     EISSN: None     Source Type: Journal    
DOI: 10.1177/001857870303800308     Document Type: Review

References (38)

1. Abilify [package literature]. Otsuka Pharmaceutical; November 2002.
2. 2 receptors. J Pharmacol Exp Ther. 2002;302:381-9.
3. 1A receptor. Eur J Pharmacol. 2002;441:137-40.
4. Kikuchi T, et al. Aripiprazole: A dopamine-serotonin system stabilizer [abstract]. Biol Psychiatry. 2002;51:23S.
5. Lawler CP, et al. Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes. Neuropsychopharmacology. 1999;20:612-27.
6. Stahl SM. Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, Part 1: "Goldilocks" actions at dopamine receptors. J Clin Psychiatry. 2001;62:841-2.
7. 2 dopamine receptor [abstract]. FASEB J. 1998;12(4, suppl):A456.
8. Semba J, et al. Behavioural and neurochemical effects of OPC-14597, a novel antipsychotic drug, on dopaminergic mechanisms in rat brain. Neuropharmacology. 1995;34:785-91.
9. Fujikawa M, et al. Partial agonistic effects of OPC-14597, a potential antipsychotic agent, on yawning behavior in rats. Pharmacol Biochem Behav. 1996;53:903-9.
10. 2 receptors [abstract]. Schizophrenia Res. 2001;49(1-2, suppl):88.
11. Altar CA, et al. The benefits of weak D-2 agonism: Autoreceptor activation and functional postsynaptic antagonism by the antipsychotic aripiprazole [abstract]. Schizophrenia Res. 1999;36(1-3):305.
12. Yokoi F, et al. PET studies of aripiprazole show high D2/D3 receptor occupancy without EPS [abstract]. Biol Psychiatry. 2002;51:17S.
13. Amano T, et al. Antagonizing effects of a novel antipsychotic quinolinone derivative (OPC-14597) on dopaminergic inhibition of neuronal activities in the nucleus accumbens. Prog Neuro-Psychopharmacol Biol Psychiat. 1995;19:105-16.
14. Momiyama T, et al. Inhibition by a putative antipsychotic quinolinone derivative (OPC-14597) of dopaminergic neurons in the ventral tegmental area. Eur J Pharmacol. 1996;310:1-8.
15. 2 receptor following repeated treatment in the rat striatum. Eur J Pharmacol. 1997;321:105-11.
16. Matsubayashi H, et al. Inhibition by aripiprazole of dopaminergic inputs to striatal neurons from substantia nigra. Psychopharmacology. 1999;146:139-43.
17. Oshiro Y, et al. Novel antipsychotic agents with dopamine autoreceptor agonist properties: Synthesis and pharmacology of 7-[4-(4-phenyl-1-piperazinyl) buyoxy]-3,4-dihydro-2(1H)-quinolinone derivatives. J Med Chem. 1998;41:658-67.
18. Sugiyama A, et al. In vivo canine model comparison of cardiohemodynamic and electrophysiological effects of a new antipsychotic drug aripiprazole (OPC-14597) to haloperidol. Toxicol Appl Pharmacol. 2001;173:120-8.
19. Inoue A, et al. Differential effects on D2 dopamine receptor and prolactin gene expression by haloperidol and aripiprazole in the rat pituitary. Mol Brain Res. 1998;55:285-92.
20. Inoue T, et al. Effects of the novel antipsychotic agent 7-(4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butyloxy}-3,4-dihydro-2(1H)- quinolinone (OPC-14597) on prolactin release from the rat anterior pituitary gland. J Pharmacol Exp Ther. 1996;277:37-43.
21. Blumer JL, et al. Pharmacokinetics (PK), tolerability and safety of aripiprazole (AR) in children (C) and adolescents (AD) with conduct disorder [abstract]. Clin Pharmacol Ther. 2002;71:P5.
22. Mallikaarjun S, et al. The effects of age and gender on the pharmacokinetics of aripiprazole [abstract]. Clin Pharmacol Ther. 2002;71:P66.
23. Mallikaarjun S, et al. The effects of hepatic impairment on the pharmacokinetics of aripiprazole [abstract]. Clin Pharmacol Ther. 2002;71:P66.
24. Anonymous. APA: Antipsychotic, aripiprazole, continues to show efficacy in schizoaffective disease, few side effects [press release]. Doctor's Guide. 2001;May 8. www.pslgroup.com/dg/1FA3F6.htm. Accessed January 30, 2002.
25. Saha A, et al. Efficacy and safety of aripiprazole and risperidone vs. placebo in patients with schizophrenia and schizoaffective disorder [poster]. 54th Annual Meeting of the American Psychiatric Association; May 2001.
26. Yeung PP, et al. Aripiprazole versus placebo and risperidone in schizophrenia and schizoaffective disorder [abstract]. Biol Psychiatry. 2002;51:121S.
27. National Institute of Mental Health. Protocol Number: 01-M-0103. Childhood onset psychotic disorders: Double-blind comparison of risperidone and aripiprazole. NIH Clinical Research Studies. www. clinicalstudies.info.nih. gov/detail/A_2001-M-0103.html. Accessed January 30, 2002.
28. Saha AR, et al. Safety and efficacy profile of aripiprazole, a novel antipsychotic [abstract]. Schizophrenia Res. 1999;36(1-3):295.
29. Petrie JL, et al. Acute and long-term efficacy and safety of aripiprazole: A new atypical antipsychotic [abstract]. Schizophrenia Res. 1998;29(1-2):155.
30. Carson WH, et al. A double-blind, placebo-controlled trial of aripiprazole and haloperidol [abstract]. Schizophrenia Res. 2001;49(1-2, suppl):221-2.
31. Kane J, et al. Efficacy of aripiprazole in psychotic disorders: Comparison with haloperidol and placebo [abstract], Schizophrenia Res. 2000;41(1):39.
32. Anonymous. APA: Aripiprazole shows promising efficacy in schizophrenia [press release]. Doctor's Guide. 2000;May 16. www.pslgroup.com/dg/1D1EE6.htm. Accessed January 30, 2002.
33. Zimbroff DL, Saha A. A double-blind, placebo-controlled trial of aripiprazole and haloperidol in patients with schizophrenia or schizoaffective disorder [abstract]. 41st New Clinical Drug Evaluation Unit Meeting. National Institute of Mental Health. 2001; Poster session III-68. www.nimh.nih.gov/ncdeu/abstracts2001/ncdeu3068.cfm. Accessed February 14, 2002.
34. Kane JM, et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry. 2002;63:763-71.
35. Kern RS, et al. An open-label comparison of the neurocognitive effects of aripiprazole versus olanzapine in patients with stable psychosis [abstract]. Schizophrenia Res. 2001;49(1-2, suppl):234.
36. Cornblatt BA, et al. Neurocognitive effects of aripiprazole versus olanzapine in patients with stable psychosis [abstract]. Biol Psychiatry. 2002;51:165S.
37. Canive JM, et al. Spontaneous brain magnetic activity in schizophrenia patients treated with aripiprazole. Psychopharmacol Bull. 1998;34:101-5.
38. Larson GL, et al. Prior exposure to typical or atypical antipsychotics as a factor of aripiprazole's effect on weight [abstract]. 41st New Clinical Drug Evaluation Unit Meeting. National Institute of Mental Health. 2001; Poster session III-85. www.nimh.nih.gov/ncdeu/abstracts2001/ncdeu3085.cfm. Accessed February 14, 2002.